Plain-English translation of NCT06189820 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pulmonary Fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers want to understand whether a protein called fibroblast activation protein (FAP) can be used as a biological marker—a measurable sign in blood, breathing samples, or imaging—to help diagnose and monitor lung scarring diseases like idiopathic pulmonary fibrosis. The study will collect samples and perform specialized scans on patients with different types of lung fibrosis, some before and after they start treatment, to see if FAP levels change in ways that could help doctors.
Lung scarring diseases are difficult to diagnose and hard to track over time. If doctors could use a simple blood test or marker to better understand who has the disease and how it's progressing, it could lead to earlier detection and more personalized treatment decisions.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may donate blood samples, breathing samples, or tissue that's already been stored at the hospital. Some participants will have specialized imaging scans (called FAPI PET/CT) performed before and after they start or change a treatment—these scans use a small radioactive tracer to show where the scarring protein is active in your lungs. The study team will track whether the protein levels and scan results change over time and match them with how your lungs are doing.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Belgium